一个基于血液的转录基因签名分层了严重的克罗恩病,并定义了潜在的可向治疗途径
Rivkah Gonsky1, Evan Adams2, Alka A Potdar1
1F. Widjaja Inflammatory Bowel Institute, Cedars-Sinai, Los Angeles, CA, United States.
研究人员根据T细胞概况确定了两个克罗恩病 (CD) 患者亚组. 一个子组 (CD-PBmu) 显示出与严重疾病和术后复发相关的独特分子特征,表明有针对性的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 基因组学就是基因组学.
背景情况:
- 克罗恩氏病 (CD) 管理通常需要手术,突出需要更好的预后工具和向治疗.
- 在CD患者中确定不同的分子通路对于改善患者分层,治疗策略和生物标志物发现至关重要.
研究的目的:
- 根据手术时的T细胞转录概况,将克罗恩病患者分为分组.
- 识别与疾病严重程度,术后结果和CD治疗反应相关的分子特征.
主要方法:
- 从100名CD和17名非IBD手术患者的血液和粘膜样本中净化CD3+T细胞.
- 转录概况,遗传转录风险评分 (TRS) 分析和T细胞子集组成分析.
- 在抗TNF治疗耐药性CD患者队列中验证CD-PBmu亚型.
主要成果:
- 确定了两个CD患者亚组:CD-PBT (与非IBD集群) 和CD-PBmu (粘膜状表达特征).
- CD-PBmu亚组表现出差异性基因表达,TRS升高,以及与近部疾病,术后复发和微生物抗原活性相关的特异性T细胞亚组.
- 确定了CD-PBmu的42个基因分类器,与TRS,临床严重程度和蛋白质激酶信号通路有关.
结论:
- CD-PBmu分子签名可能可以识别严重的CD患者.
- 基于分子途径的向治疗早期启动可能有利于CD-PBmu亚组.
- 这种分类方法为克罗恩病的预后准确性和个性化治疗策略的提高提供了潜力.
更多相关视频
03:08Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
10:37Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Pharmacogenomics: Identification of New Drug Targets
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
